Last reviewed · How we verify

NCT04211727

Affinity: Hospital Trial

Completed Last updated 29 March 2022
What this trial tests

trial testing Capillary finger prick blood sample in Cancer in 247 participants. Completed in 17 January 2022.

Timeline
26 October 2020
Primary endpoint
17 January 2022
17 January 2022

Quick facts

Lead sponsorEntia Ltd
StatusCompleted
Study typeOBSERVATIONAL
Enrollment247
Start date26 October 2020
Primary completion17 January 2022
Estimated completion17 January 2022
Sites1 location across United Kingdom

Drugs / interventions tested

Conditions studied

Sponsor

Entia Ltd

Who can join

18 and older, any sex, with Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Method comparison study to compare the Affinity prototype device using a capillary blood sample against routine venous laboratory results, in patients undergoing systemic anti-cancer therapy (SACT). Tests will be performed by healthcare professionals (Cohort 1) and participants self-testing (Cohort 2)

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Cancer

Currently open trials in the same condition.

Other Entia Ltd trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04211727.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing